Home  »  Companies   »  CVS Health Corporation (CVS): A Technical Analysis...

CVS Health Corporation (CVS): A Technical Analysis

CVS Health Corporation (NYSE: CVS) has a higher price-to-earnings ratio of 24.30x compared to its average ratio. compared to its average ratio and a 36-month beta value of 0.62. Analysts have mixed views on the stock, with 13 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 0 as “sell.”

The average price point forecasted by analysts for CVS Health Corporation (CVS) is $112.17, which is $37.69 above the current market price. The public float for CVS is 1.28B, and currently, short sellers hold a 1.15% ratio of that float. The average trading volume of CVS on March 17, 2023 was 8.90M shares.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


CVS) stock’s latest price update

CVS Health Corporation (NYSE: CVS)’s stock price has increased by 0.57 compared to its previous closing price of 75.40. However, the company has seen a fall of -1.52% in its stock price over the last five trading days. The Wall Street Journal reported on 03/01/23 that Congress Investigates How Pharma Middlemen Affect Drug Prices

CVS’s Market Performance

CVS Health Corporation (CVS) has seen a -1.52% fall in stock performance for the week, with a -14.34% decline in the past month and a -25.06% plunge in the past quarter. The volatility ratio for the week is 2.02%, and the volatility levels for the past 30 days are at 1.78% for CVS. The simple moving average for the last 20 days is -8.14% for CVS stock, with a simple moving average of -19.64% for the last 200 days.

Analysts’ Opinion of CVS

Many brokerage firms have already submitted their reports for CVS stocks, with Evercore ISI repeating the rating for CVS by listing it as a “In-line.” The predicted price for CVS in the upcoming period, according to Evercore ISI is $100 based on the research report published on January 03rd of the current year 2023.

Morgan Stanley, on the other hand, stated in their research note that they expect to see CVS reach a price target of $119, previously predicting the price at $124. The rating they have provided for CVS stocks is “Overweight” according to the report published on November 23rd, 2022.

Loop Capital gave a rating of “Buy” to CVS, setting the target price at $120 in the report published on June 17th of the previous year.

CVS Trading at -12.00% from the 50-Day Moving Average

After a stumble in the market that brought CVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.87% of loss for the given period.

Volatility was left at 1.78%, however, over the last 30 days, the volatility rate increased by 2.02%, as shares sank -14.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.38% lower at present.

During the last 5 trading sessions, CVS fell by -1.52%, which changed the moving average for the period of 200-days by -22.66% in comparison to the 20-day moving average, which settled at $81.93. In addition, CVS Health Corporation saw -18.63% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CVS starting from Moriarty Thomas M, who sale 137,466 shares at the price of $98.36 back on Dec 15. After this action, Moriarty Thomas M now owns 608,129 shares of CVS Health Corporation, valued at $13,521,180 using the latest closing price.

Lotvin Alan, the EVP&President-PharmacyServices of CVS Health Corporation, sale 22,541 shares at $104.00 during a trade that took place back on Aug 04, which means that Lotvin Alan is holding 109,183 shares at $2,344,264 based on the most recent closing price.

Stock Fundamentals for CVS

Current profitability levels for the company are sitting at:

  • +5.08 for the present operating margin
  • +16.92 for the gross margin

The net margin for CVS Health Corporation stands at +1.29. Equity return is now at value 5.70, with 1.80 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.


To put it simply, CVS Health Corporation (CVS) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.